# A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

> **NCT07335562** · PHASE3 · RECRUITING · sponsor: **Juno Therapeutics, Inc., a Bristol-Myers Squibb Company** · enrollment: 92 (estimated)

## Conditions studied

- Systemic Sclerosis

## Interventions

- **DRUG:** BMS-986353
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Tocilizumab
- **DRUG:** Rituximab
- **DRUG:** Nintedanib

## Key facts

- **NCT ID:** NCT07335562
- **Lead sponsor:** Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-29
- **Primary completion:** 2028-11-14
- **Final completion:** 2030-11-11
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07335562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07335562, "A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT07335562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*